BioXcel Therapeutics to Report Second Quarter 2024 Financial Results on August 6, 2024
NEW HAVEN, Conn., July 30, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence...
NEW HAVEN, Conn., July 30, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence...
The esteemed annual symposium explores the most urgent questions facing our future BOSTON, July 29, 2024 /PRNewswire/ -- The Chopra...
AAIC Poster Presentation Highlights XPro's™ Significant Effects on a Wide Range of Synaptic Proteins and Pathways BOCA RATON, Fla., July...
MALVERN, Pa., July 29, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing,...
This data supports the potential of plasma ASC levels as a biomarker for early stages of cognitive decline, based on...
PURCHASE, N.Y., July 26, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage...
Topline results demonstrated a favorable safety profile and tolerability across four ascending dose levels in healthy volunteers and showed dose...
$30.3 million financing upfront with up to an additional $92.4 million tied to exercise of warrants, with certain of the...
If approved, Yuvanci® would become the only single tablet combination for treatment for patients with PAH Johnson & Johnson’s comprehensive...
Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare...
- Demonstrates Neurophet AQUA AD for AD treatments such as Leqembi and Kisunla - Introduces updated version of Neurophet SCALE...
Nerivio, currently indicated for use in ages 12 and older, demonstrates study results in younger children with migraine. BRIDGEWATER, N.J. and...
Life sciences platform enhanced to make cognitive assessments easier and more precise BOSTON, July 24, 2024 /PRNewswire/ -- Linus Health, a...
Company's virtual therapeutic programs and proprietary risk stratification algorithm support proactive detection of and intervention for cognitive decline BOSTON, July...
Veradigm Network EHR data enables a deeper understanding of the patient journey and disorder progression NEW YORK and CHICAGO, July...
ROCKVILLE, Md., July 23, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and...
ViewMind's Ocular Digital Phenotyping solution is a holistic approach to brain and mental health that builds trust through technology, enabling...
BURLINGTON, Mass. and JERUSALEM, July 23, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
Group to Advise on the Application of Ovid’s Novel Pipeline Programs to Broader Disorders of the BrainNeurologists/epileptologists Dr. Imad Najm...
MORRISTOWN, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to pushing the boundaries...